{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:36:13Z","timestamp":1780360573492,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejca.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T07:47:45Z","timestamp":1578469665000},"page":"78-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Positron-emission tomography\u2013based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma"],"prefix":"10.1016","volume":"126","author":[{"given":"Connie L.","family":"Batlevi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fushen","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Alperovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Gerecitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia M.","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"von Keudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman E.","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.12.006_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.12.006_bib2","first-page":"5","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CAA Cancer J Clin"},{"key":"10.1016\/j.ejca.2019.12.006_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib4","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2019.12.006_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2019.12.006_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.12.006_bib7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading","volume":"17","author":"W\u00f6hrer","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2019.12.006_bib10","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1002\/cncr.30672","article-title":"[(18) F]-FDG PET\/CT in the staging and management of indolent lymphoma: a prospective multicenter PET registry study","volume":"123","author":"Metser","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.12.006_bib11","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.12.006_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2019.12.006_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib15","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib16","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.ejca.2019.12.006_bib20","series-title":"A language and environment for statistical computing","author":"Team","year":"2013"},{"key":"10.1016\/j.ejca.2019.12.006_bib21","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib22","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib23","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib24","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2019.12.006_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdw026","article-title":"Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","article-title":"An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed\/refractory follicular B-cell lymphoma","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.12.006_bib27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-CT215","article-title":"CHRONOS-1: open-label, uncontrolled phase II trial of intravenous phosphatidylinositol-3 kinase alpha\/delta inhibitor copanlisib in patients with relapsed, indolent Non-Hodgkin's lymphomas (iNHL)","volume":"75","author":"Dreyling","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2019.12.006_bib28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.12.006_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1798.1798","article-title":"MAGNIFY: phase IIIb randomized study of lenalidomide plus rituximab (R) followed by lenalidomide vs. Rituximab maintenance in subjects with relapsed\/refractory follicular, marginal zone, or mantle cell lymphoma","volume":"128","author":"Andorsky","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.12.006_bib31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib32","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.12.006_bib33","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.006_bib34","article-title":"Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","author":"Dreyling","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2019.12.006_bib35","series-title":"Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma","author":"Freeman","year":"2019"},{"key":"10.1016\/j.ejca.2019.12.006_bib36","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2018-99-116686","article-title":"Baseline suvmax did not predict histological transformation from follicular lymphoma to aggressive lymphoma in the phase III GALLIUM study","volume":"132","author":"Mir","year":"2018","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:13Z","timestamp":1760732773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919308585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":36,"alternative-id":["S0959804919308585"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron-emission tomography\u2013based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}